These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 29689643)
41. FOXF2 deficiency promotes hepatocellular carcinoma metastasis by inducing mesenchymal-epithelial transition. Dou C; Jin X; Sun L; Zhang B; Han M; Li T Cancer Biomark; 2017 Jul; 19(4):447-454. PubMed ID: 28582850 [TBL] [Abstract][Full Text] [Related]
42. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816 [TBL] [Abstract][Full Text] [Related]
43. Involvement of PI3K/Akt pathway in the inhibition of hepatocarcinoma cell invasion and metastasis induced by SASH1 through downregulating Shh-Gli1 signaling. Sun C; Zhang Z; He P; Zhou Y; Xie X Int J Biochem Cell Biol; 2017 Aug; 89():95-100. PubMed ID: 28600143 [TBL] [Abstract][Full Text] [Related]
44. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. Hou KZ; Fu ZQ; Gong H World J Gastroenterol; 2015 Jan; 21(2):475-83. PubMed ID: 25593462 [TBL] [Abstract][Full Text] [Related]
45. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1. Zhao XL; Sun T; Che N; Sun D; Zhao N; Dong XY; Gu Q; Yao Z; Sun BC J Cell Mol Med; 2011 Mar; 15(3):691-700. PubMed ID: 20219012 [TBL] [Abstract][Full Text] [Related]
46. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target. Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986 [TBL] [Abstract][Full Text] [Related]
47. TRAF4 Regulates Migration, Invasion, and Epithelial-Mesenchymal Transition via PI3K/AKT Signaling in Hepatocellular Carcinoma. Liu K; Wu X; Zang X; Huang Z; Lin Z; Tan W; Wu X; Hu W; Li B; Zhang L Oncol Res; 2017 Sep; 25(8):1329-1340. PubMed ID: 28256185 [TBL] [Abstract][Full Text] [Related]
48. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway. Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952 [TBL] [Abstract][Full Text] [Related]
49. Scorpion inhibits epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma. Yan YQ; Xie J; Wang JF; Shi ZF; Zhang X; Du YP; Zhao XC Exp Biol Med (Maywood); 2018 Apr; 243(7):645-654. PubMed ID: 29486578 [TBL] [Abstract][Full Text] [Related]
50. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells. Wu WL; Wang WY; Yao WQ; Li GD Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886 [TBL] [Abstract][Full Text] [Related]
51. MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. Feng XJ; Pan Q; Wang SM; Pan YC; Wang Q; Zhang HH; Zhu MH; Zhang SH Tumour Biol; 2016 Aug; 37(8):11457-67. PubMed ID: 27010469 [TBL] [Abstract][Full Text] [Related]
52. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence. Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919 [TBL] [Abstract][Full Text] [Related]
53. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433 [TBL] [Abstract][Full Text] [Related]
54. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway. Ni Q; Chen Z; Zheng Q; Xie D; Li JJ; Cheng S; Ma X Cancer Sci; 2020 May; 111(5):1500-1513. PubMed ID: 31997489 [TBL] [Abstract][Full Text] [Related]
55. Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib. Yang J; Wang J; Luo J Pathol Res Pract; 2019 Oct; 215(10):152565. PubMed ID: 31387809 [TBL] [Abstract][Full Text] [Related]
56. HAX-1 promotes the migration and invasion of hepatocellular carcinoma cells through the induction of epithelial-mesenchymal transition via the NF-κB pathway. Hu YL; Feng Y; Ma P; Wang F; Huang H; Guo YB; Li P; Mao QS; Xue WJ Exp Cell Res; 2019 Aug; 381(1):66-76. PubMed ID: 31047882 [TBL] [Abstract][Full Text] [Related]
57. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma. Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082 [TBL] [Abstract][Full Text] [Related]
58. Interleukin-17A inhibits cell autophagy under starvation and promotes cell migration via TAB2/TAB3-p38 mitogen-activated protein kinase pathways in hepatocellular carcinoma. Zhou Y; Wu PW; Yuan XW; Li J; Shi XL Eur Rev Med Pharmacol Sci; 2016; 20(2):250-63. PubMed ID: 26875893 [TBL] [Abstract][Full Text] [Related]
59. MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma. Jin M; Wang J; Ji X; Cao H; Zhu J; Chen Y; Yang J; Zhao Z; Ren T; Xing J J Exp Clin Cancer Res; 2019 Mar; 38(1):136. PubMed ID: 30909929 [TBL] [Abstract][Full Text] [Related]
60. miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. Tao ZH; Wan JL; Zeng LY; Xie L; Sun HC; Qin LX; Wang L; Zhou J; Ren ZG; Li YX; Fan J; Wu WZ J Exp Med; 2013 Apr; 210(4):789-803. PubMed ID: 23478189 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]